T cells are small white blood cells that play an important part in immune defenses. T cells can be enhanced in the laboratory to recognize a protein called the Wilms’ Tumor gene (WT1), which is present on some tumors. About 80 percent of ovarian cancers have the WT1 protein. Laboratory studies have shown that T cells from ovarian cancer patients that have been taught to recognize the WT1 protein can kill tumor cells.
The purpose of this study is to evaluate the safety of WT1-targeted T cell treatment in patients with recurrent or persistent advanced ovarian, primary peritoneal, or fallopian tube cancers that contain the WT1 protein and to see if patients develop an immune response as a result of the treatment.
Patients in this study will be treated at five different dose levels. The first three groups will receive T cells only. The fourth and fifth groups will receive T cells and chemotherapy with cyclophosphamide and fludarabine.